Erythropoietin prevents chemotherapy-induced anemia: case report.
A thirty-seven year old male patient with heavily pretreated metastatic testicular carcinoma received escalating doses of recombinant human erythropoietin (EPO) before and throughout chemotherapy. Whereas previous chemotherapy regimens repeatedly caused anemic situations in this patient (hemoglobin (HB) 7.0 g/dl requiring multiple transfusions of red blood cells), EPO given as an i.v. bolus injection at escalating doses of 150 to 300 U/kg body weight (BW) twice/week, starting two weeks prior to the identical myelosuppressive treatment protocol, maintained HB at levels above 8.8 g/dl and thus obviated the need for erythrocyte transfusion. EPO was discontinued after 9 weeks of administration when the patient had achieved a hematocrit (HCT) of 41.1% and a HB of 12.7 g/dl. However, erythropoiesis continued to recover for the next 7 weeks reaching a HCT of 42.4% and a HB of 14.3 g/dl, although the next identical chemotherapy cycle had been given within this period. Along with the rise in HB, ferrokinetics changed significantly as measured by serum ferritin, which was reduced to one third at the end of EPO therapy after only 9 weeks (from 979 ng/ml to 320 ng/ml). No side effects due to EPO administration occurred. These data provide first evidence for efficacy of EPO in chemotherapy-induced anemia and may open new avenues for its clinical application.
Oster
W
W
Department of Hematology, Mainz, Federal Republic of Germany.
Herrmann
F
F
Cicco
A
A
Gamm
H
H
Zeile
G
G
Brune
T
T
Lindemann
A
A
Schulz
G
G
Mertelsmann
R
R
D000328:Adult; D000740:Anemia / Q000139:chemically induced / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D008297:Male
D004921:Erythropoietin